Inhibition of Proprotein Convertase Subtilisin/Kexin-9 After Kidney Transplant: Single-Center Experience Among...

Area of Science:

• Nephrology
• Cardiology
• Pharmacology

Background:

• Kidney transplant recipients have high cardiovascular risk.
• The efficacy of evolocumab in reducing lipids in this population is not well-established.
• Hypercholesterolemia is a significant concern post-transplant.

Purpose of the Study:

• To evaluate the efficacy and safety of evolocumab in reducing lipids and cardiovascular events in kidney transplant recipients.
• To compare evolocumab with standard statin therapy in this high-risk group.

Main Methods:

• A randomized controlled study involving 197 kidney transplant recipients with high cardiovascular risk.
• Patients received either evolocumab (140 mg/2 weeks) or standard statin therapy.
• Follow-up included clinical assessments and laboratory investigations over 24 months.

Main Results:

• Evolocumab significantly reduced high baseline cholesterol levels compared to statin therapy.
• No significant differences in cardiovascular events, patient, or graft outcomes were observed between groups.
• Two cases of acute myocardial infarction and one atrial fibrillation occurred in the statin group.

Conclusions:

• Proprotein convertase subtilisin/kexin-9 inhibitors, like evolocumab, are safe and effective adjuncts to statins for hypercholesterolemia post-kidney transplant.
• Evolocumab may help minimize cardiovascular events in high-risk patients.
• Longer-term, larger trials are necessary to confirm effects on cardiovascular complications and survival.